QTC prolongation

[키워드] 48 hour addition Administered adverse effect allergy Alpha anticipated assumed baseline blinded to treatment block clinical Clinical outcome Comorbidity COVID-19 data management Day death determine dissemination drug interaction element eligible eligible participant enrolment evaluate evaluated excluded expected group hospital hospitalised hospitalised patient Hydroxychloroquine independent Intensive intensive care Intervention intervention arms invasive investigator investigator-initiated Laboratory Lopinavir management men New no interaction non-invasive ventilation nucleic acid number objective Open-label outcome participant Patient platform Primary outcome proportion Proportion of participant protocol provided QTC prolongation randomisation randomised randomised controlled trial receive receiving recruited reduce Registered registry representing required researcher Respiratory Support risk Ritonavir Sample size SARS-CoV-2 SARS-COV-2 infection secondary outcome sequence significance level Standard of care status stratified study drug Study protocol Tablet total sample size treated Trial two-sided unblinding ventilatory support Virological website women
[DOI] 10.1186/s13063-020-04576-9 PMC 바로가기 [Article Type] Letter